Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepak Sampath

Showing results (11-20 of 100) with videos related to

Pageof 10
Sort By:
Science Translational Medicine|September 10, 2010
Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancerJeffrey J Wallin, Jane Guan, Wei Wei Prior, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer modelsNguyen Tan, Mehnaz Malek, Jiping Zha, et al.
Cancer Discovery|November 18, 2017
Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor VenetoclaxJoel D Leverson, Deepak Sampath, Andrew J Souers, et al.
Cancer Research|January 28, 2010
Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumorsKyle A Edgar, Jeffrey J Wallin, Megan Berry, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|January 10, 2024
Preclinical characterization of the absorption and disposition of the brain penetrant PI3K/mTOR inhibitor paxalisib and prediction of its pharmacokinetics and efficacy in humanLaurent Salphati, Jodie Pang, Bruno Alicke, et al.
Cancer Cell|May 5, 2009
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941Teemu T Junttila, Robert W Akita, Kathryn Parsons, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 15, 2012
Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in humanLaurent Salphati, Jodie Pang, Emile G Plise, et al.
The EMBO Journal|July 10, 2012
Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathwayGuanglei Zhuang, Xiumin Wu, Zhaoshi Jiang, et al.
Cancer Research|March 22, 2018
Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML CellsMohamed Rahmani, Jewel Nkwocha, Elisa Hawkins, et al.
Molecular Cancer Therapeutics|October 14, 2003
MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivoDeepak Sampath, Carolyn M Discafani, Frank Loganzo, et al.
Pageof 10

Showing results (11-20 of 100) with videos related to

Sort By:
Pageof 10
Science Translational Medicine|September 10, 2010
Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancerJeffrey J Wallin, Jane Guan, Wei Wei Prior, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer modelsNguyen Tan, Mehnaz Malek, Jiping Zha, et al.
Cancer Discovery|November 18, 2017
Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor VenetoclaxJoel D Leverson, Deepak Sampath, Andrew J Souers, et al.
Cancer Research|January 28, 2010
Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumorsKyle A Edgar, Jeffrey J Wallin, Megan Berry, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|January 10, 2024
Preclinical characterization of the absorption and disposition of the brain penetrant PI3K/mTOR inhibitor paxalisib and prediction of its pharmacokinetics and efficacy in humanLaurent Salphati, Jodie Pang, Bruno Alicke, et al.
Cancer Cell|May 5, 2009
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941Teemu T Junttila, Robert W Akita, Kathryn Parsons, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 15, 2012
Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in humanLaurent Salphati, Jodie Pang, Emile G Plise, et al.
The EMBO Journal|July 10, 2012
Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathwayGuanglei Zhuang, Xiumin Wu, Zhaoshi Jiang, et al.
Cancer Research|March 22, 2018
Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML CellsMohamed Rahmani, Jewel Nkwocha, Elisa Hawkins, et al.
Molecular Cancer Therapeutics|October 14, 2003
MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivoDeepak Sampath, Carolyn M Discafani, Frank Loganzo, et al.
Pageof 10